DANBIO + Swedish register SGR linked to national birth registers (matched 1:10): RA-pregnancies: higher preterm birth (OR 1.92, 95CI 1.56-2.35) and small gestational age (OR 1.93, 95CI 1.45-2.57). Association strengthened by high disease activity. #OP0210 @Rheumnow #EULAR2021 https://t.co/Fjm0uxCPgC

KEEPsAKE 2: Risankizumab RCT in Bio-IR or csDMARD-IR active PsA. Primary endpoint ACR20 W24 met with 51.3% vs 26.5% in PBO group (P < .001) and ACR50 26.3% vs 9.3%. No particular safety signal. #OP0228 @Rheumnow #EULAR2021 https://t.co/HZv8qoc4sz

What is the impact of RA on fertility in men: #OP0211 and #OP0212 @Rheumnow #EULAR2021

COSMOS study: Guselkumab RCT in PsA pts TNFi-resistants (1 or 2) 44.4% of GUS vs 19.8% of PBO pts achieved ACR20 at w24 (p<0.001) and GUS > PBO for most secondary endpoints. Tolerance: 18% vs. 20% infections/SI. #OP0230 @Rheumnow #EULAR2021 @DrLauraCoates https://t.co/fFle2OR8KM

Retrospective RA cohort study: overall risk of dementia ⬆️ in RA (HR 1.38; 95%CI 1.04-1.83) BUT 10-year cumulative incidence of dementia ⬇️: 12.7% in 1980s 7.2% in 1990s 2000s 6.2% Risk no longer significantly ⬆️ for patients w/ RA onset in 2000s! @RheumNow #EULAR2021 #OP0216 https://t.co/TVRTTJjvno

Serious infections and BioDMARDs: what is the confounding factor? BSRBR-RA: 33,916 RA treated w/ BioDMARDs with 62,532 years of follow-up, 2036 SI. HR of SI no longer different among BioDMARDs when adjusted for the line of therapy! #OP0241@Rheumnow #EULAR2021 https://t.co/UG9WrXP7RD

COVID-19 Global Rheum Alliance Registry: prediction of ARDS by machine learning algorithm in a model using 42 variables including: demographics, rheumatic D, meds and comorb with Sens 0.81, Spe 0.49, AUC 075. Interesting model for close monitoring #OP0288 @Rheumnow #EULAR2021 https://t.co/9YY0jzDx59

PreCARA: analysis of cord blood levels of TNFi in RA pregnancy: -CTZ n=68 measured in 5.9% and low concentrations -ETA n=28 not detected -ADA n=24 in 50% low C -INF n=13 in 61.5% low C for both even in patients who discontinued at GA 20 weeks. @RheumNow #EULAR2021 #POS0202 https://t.co/osBrmbepkb

D2T RA is definitely a complex disease interlinked w/ multimorbidity @ElenaNikiUK reminds us of the importance of: 1) Detecting comorbidities 2) Adress multimorbidity to 3) Provide patient-centred care tailored to their specific needs #EULAR2021 @RheumNow https://t.co/ebyYDqnQ1k

RA: total comorbidity count ≤1 (vs ≥ 2) predicts LDA/Rem @6 months ttmt [OR 4.1 p=0.005], while RDCI=0 (vs. ≥ 1) predicts HAQ improvement ≥0.25 [OR 2.6 p=0.046] Basal predictors of D2TRA: RDCI≥ 1(vs. 0) [OR 3.3 -p = 0.024], female sex and age #OP02999 @Rheumnow #EULAR2021 https://t.co/wc16oCKcix

#EULAR2021 key note speaker, Mark Pollock, is a model of resiliency after blindness and later, a spinal cord injury. "Sometimes we have the luxury of choosing our challenges and sometimes the challenges choose us." @RheumNow

Poster from Cohen et al #POS0220 at #EULAR2021 No new safety signals in UPA treated RA patients in 4.5 years of SELECT clinical trial data. @RheumNow https://t.co/Q48ZaUee8q

ASTERA phase 3 analysis: NTK leads to decline of disease activity in AS pts irrespectively of sacroiliitis on MRI. Abstract #OP0142 #EULAR2021 @RheumNow https://t.co/51f18728ZB https://t.co/qZcsMlKqbW

• http://ow.ly/Uo5w50F1kcV

Real world data from German AQUILA: SEC improved PsA dz activity in M & F pts. Female pts had higher dz burden prior to tx. #EULAR2021 Poster #POS0123 @RheumNow https://t.co/cNIN6yqN0j https://t.co/nPZLDztxQP

• https://ard.bmj.com/content/80/Suppl_1/780.full

Phase 2 Deucravacitinib, oral, selective TYK2i results: Analyses confirmed the efficacy of deucravacitinib vs PBO across TNFi & body weight subgroups. Safety profile similar to that found in PsO trials. Abstract #OP0227 #EULAR2021 @RheumNow https://t.co/BBvn5MaXPp https://t.co/jWFhpmkuC5

• http://ow.ly/MJLf50F2NhP